8-K: Viking Therapeutics Announces Positive Phase 2 Results for Obesity Drug VK2735

Viking Therapeutics' VK2735 demonstrated significant weight loss in a Phase 2 trial, achieving primary and secondary endpoints with up to 13.1% placebo-adjusted mean weight loss.

Summary

• Viking Therapeutics announced positive top-line results from its Phase 2 VENTURE trial of VK2735, a dual GLP-1/GIP receptor agonist, for the treatment of obesity.
• The trial met its primary endpoint, showing statistically significant reductions in body weight compared to placebo.
• Patients receiving VK2735 experienced up to 14.7% mean weight loss from baseline and up to 13.1% placebo-adjusted mean weight loss after 13 weeks.
• Weight loss was progressive throughout the study, with no plateau observed at 13 weeks.
• Up to 88% of patients in the VK2735 treatment groups achieved at least 10% weight loss, compared to 4% in the placebo group.
• The drug was generally safe and well-tolerated, with most adverse events being mild or moderate.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 2 trial, with strong efficacy and a generally acceptable safety profile. The lack of a weight loss plateau and the high percentage of patients achieving significant weight loss are particularly encouraging.

Positives

• The drug demonstrated significant weight loss, with up to 13.1% placebo-adjusted mean weight loss.
• A high percentage of patients, up to 88%, achieved at least 10% weight loss.
• The weight loss was progressive with no plateau observed at 13 weeks.
• VK2735 was generally safe and well-tolerated, with most adverse events being mild or moderate.
• Discontinuation rates were low and balanced between the treatment and placebo groups.

Negatives

• Nausea was reported in 43% of patients receiving VK2735, although most cases were mild.
• Vomiting was reported in 18% of VK2735-treated patients, while none was reported in the placebo group.
• One patient experienced a serious adverse event of dehydration related to the study drug.

Risks

• The study reported some gastrointestinal side effects, including nausea and vomiting.
• There is a risk of serious adverse events, as one patient experienced dehydration related to the drug.
• The long-term safety and efficacy of VK2735 are still to be determined.
• The company needs to successfully navigate regulatory approvals and commercialization challenges.

Future Outlook

Viking intends to meet with the FDA to discuss next steps in the development of VK2735 and expects to report data from a Phase 1 study of an oral formulation of VK2735 later this quarter.

Management Comments

• VK2735 continues to demonstrate a promising efficacy and tolerability profile following 13 weeks of repeat dosing in obese subjects, said Brian Lian, Ph.D., chief executive officer of Viking.
• Notably, robust weight loss compared with placebo was observed early across all doses evaluated in the VENTURE study, and continued throughout the treatment period in all treatment groups.
• No evidence of a plateau was observed at Week 13 for any VK2735 dose, suggesting further weight loss might be achieved from extended dosing periods.
• We look forward to progressing this important therapy into further clinical development later this year.

Industry Context

The announcement is significant in the context of the growing market for obesity treatments, with GLP-1 and dual GLP-1/GIP agonists gaining prominence. The results position Viking as a potential competitor in this space, alongside companies like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound).

Comparison to Industry Standards

• The weight loss results of up to 13.1% placebo-adjusted mean weight loss are competitive with other GLP-1 and dual GLP-1/GIP agonists currently on the market.
• For example, Novo Nordisk's Wegovy (semaglutide) has shown around 15% weight loss in clinical trials, while Eli Lilly's Zepbound (tirzepatide) has demonstrated up to 20% weight loss.
• The 88% of patients achieving 10% weight loss is also a strong result compared to other similar treatments.
• The safety profile of VK2735 appears to be generally in line with other drugs in this class, with common side effects like nausea and vomiting, but the serious adverse event of dehydration will need further investigation.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Employees may be motivated by the progress of the company's lead drug candidate.
• Patients with obesity may benefit from this potential new treatment option.
• The results could impact the competitive landscape for pharmaceutical companies in the obesity treatment market.

Next Steps

• Viking intends to meet with the FDA to discuss next steps in the development of VK2735.
• The company plans to progress VK2735 into further clinical development later this year.
• Data from a Phase 1 study of an oral formulation of VK2735 is expected later this quarter.

Key Dates

Keywords

VK2735, obesity, weight loss, GLP-1, GIP, clinical trial, metabolic disorders, Phase 2, biopharmaceutical, Viking Therapeutics